DOCSLIB.ORG

Portfolio Holdings Listing Select Biotechnology Portfolio As of July

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Portfolio Holdings Listing Select Biotechnology Portfolio As of July Portfolio Holdings Listing Select Biotechnology Portfolio DUMMY as of July 30, 2021 The portfolio holdings listing (listing) provides information on a fund’s investments as of the date indicated. Top 10 holdings information (top 10 holdings) is also provided for certain equity and high income funds. The listing and top 10 holdings are not part of a fund’s annual/semiannual report or Form N-Q and have not been audited. The information provided in this listing and top 10 holdings may differ from a fund’s holdings disclosed in its annual/semiannual report and Form N-Q as follows, where applicable: With certain exceptions, the listing and top 10 holdings provide information on the direct holdings of a fund as well as a fund’s pro rata share of any securities and other investments held indirectly through investment in underlying non- money market Fidelity Central Funds. A fund’s pro rata share of the underlying holdings of any investment in high income and floating rate central funds is provided at a fund’s fiscal quarter end. For certain funds, direct holdings in high income or convertible securities are presented at a fund’s fiscal quarter end and are presented collectively for other periods. For the annual/semiannual report, a fund’s investments include trades executed through the end of the last business day of the period. This listing and the top 10 holdings include trades executed through the end of the prior business day. The listing includes any investment in derivative instruments, and excludes the value of any cash collateral held for securities on loan and a fund’s net other assets. Therefore, the holdings as a percent of fund net assets may not total to 100%. The presentation of investment holdings by category is similar to that used in other marketing materials. The fund’s holdings are consistent across all share classes. The top 10 holdings is presented to illustrate examples of the securities that the fund has bought and the diversity of the areas in which the fund may invest, may not be representative of the fund’s current or future investments, and may change at any time. The top 10 holdings do not include cash, cash equivalents, money market instruments, options, interest rate swaps, fixed income total return swaps and/or futures contracts. Depositary receipts, credit default swaps and equity total return swaps are normally combined with the underlying security. The most recent annual/semiannual report can be viewed at www.fidelity.com or www.institutional.fidelity.com. Forms N-Q are available on the SEC’s web site at www.sec.gov. Before investing, consider the fund’s investment objectives, risks, charges and expenses. Contact Fidelity for a prospectus containing this information. Read it carefully. 466719.7.0 TOP TEN HOLDINGS % of Net Security Name Market Value Assets AbbVie, Inc. $979,785,516 12.5% Moderna, Inc. $361,098,088 4.6% Biogen, Inc. $298,218,887 3.8% Alnylam Pharmaceuticals, Inc. $256,410,105 3.3% Vertex Pharmaceuticals, Inc. $150,621,785 1.9% Biohaven Pharmaceutical Holding Co. Ltd. $143,665,639 1.8% Arvinas Holding Co. LLC $140,167,972 1.8% Intellia Therapeutics, Inc. $135,552,002 1.7% Argenx SE ADR $125,633,999 1.6% Acceleron Pharma, Inc. $110,863,939 1.4% Top Ten Holdings Total: $2,702,017,932 34.5% 466719.7.0 Fidelity Distributors Company, LLC 500 Salem Street Not Part of Annual or Semiannual Report Smithfield, RI 02917 2 FULL HOLDINGS LISTING % of Net Security Name Market Value Assets Ticker CUSIP ISIN SEDOL Domestic Equities AbbVie, Inc. $979,785,516 12.506% ABBV 00287Y109 US00287Y1091 B92SR70 Moderna, Inc. $361,098,088 4.609% MRNA 60770K107 US60770K1079 BGSXTS3 Biogen, Inc. $298,218,887 3.806% BIIB 09062X103 US09062X1037 2455965 Alnylam Pharmaceuticals, Inc. $256,410,105 3.273% ALNY 02043Q107 US02043Q1076 B00FWN1 Vertex Pharmaceuticals, Inc. $150,621,785 1.923% VRTX 92532F100 US92532F1003 2931034 Biohaven Pharmaceutical Holding Co. Ltd. $143,665,639 1.834% BHVN VGG111961055 BZ8FXC4 Arvinas Holding Co. LLC $140,167,972 1.789% ARVN 04335A105 US04335A1051 BDZ30Q0 Intellia Therapeutics, Inc. $135,552,002 1.730% NTLA 45826J105 US45826J1051 BYZM6C2 Acceleron Pharma, Inc. $110,863,939 1.415% XLRN 00434H108 US00434H1086 BDGTXQ8 Blueprint Medicines Corp. $110,730,435 1.413% BPMC 09627Y109 US09627Y1091 BWY52P3 Seagen, Inc. $107,786,539 1.376% SGEN 81181C104 US81181C1045 BLPK4D2 TG Therapeutics, Inc. $99,456,276 1.269% TGTX 88322Q108 US88322Q1085 B828K63 Mirati Therapeutics, Inc. $99,403,662 1.269% MRTX 60468T105 US60468T1051 BBPK0J0 Adimab LLC $99,265,489 1.267% BIOH.PP Arcus Biosciences, Inc. $97,093,493 1.239% RCUS 03969F109 US03969F1093 BDZT9Y9 Apellis Pharmaceuticals, Inc. $94,087,505 1.201% APLS 03753U106 US03753U1060 BYTQ6X1 PTC Therapeutics, Inc. $86,960,958 1.110% PTCT 69366J200 US69366J2006 B17VCN9 Amgen, Inc. $79,995,633 1.021% AMGN 031162100 US0311621009 2023607 Krystal Biotech, Inc. $78,420,461 1.001% KRYS 501147102 US5011471027 BD6JX35 Fate Therapeutics, Inc. $77,971,684 0.995% FATE 31189P102 US31189P1021 BCZS820 Novavax, Inc. $77,387,351 0.988% NVAX 670002401 US6700024010 BJDQXG4 Gilead Sciences, Inc. $75,193,163 0.960% GILD 375558103 US3755581036 2369174 Arrowhead Pharmaceuticals, Inc. $74,668,706 0.953% ARWR 04280A100 US04280A1007 BYQBFJ8 Cytokinetics, Inc. $69,405,819 0.886% CYTK 23282W605 US23282W6057 BBBSBJ5 Regeneron Pharmaceuticals, Inc. $66,713,945 0.852% REGN 75886F107 US75886F1075 2730190 Natera, Inc. $65,703,903 0.839% NTRA 632307104 US6323071042 BYQRG48 Ultragenyx Pharmaceutical, Inc. $64,090,478 0.818% RARE 90400D108 US90400D1081 BJ62Z18 Incyte Corp. $58,791,182 0.750% INCY 45337C102 US45337C1027 2471950 Exact Sciences Corp. $51,527,246 0.658% EXAS 30063P105 US30063P1057 2719951 United Therapeutics Corp. $49,233,169 0.628% UTHR 91307C102 US91307C1027 2430412 Springworks Therapeutics, Inc. $48,790,724 0.623% SWTX 85205L107 US85205L1070 BGMGM89 Exelixis, Inc. $48,412,476 0.618% EXEL 30161Q104 US30161Q1040 2576941 Scholar Rock Holding Corp. $48,226,469 0.616% SRRK 80706P103 US80706P1030 BFZQ0L8 Neurocrine Biosciences, Inc. $47,359,815 0.605% NBIX 64125C109 US64125C1099 2623911 Kymera Therapeutics, Inc. $47,052,997 0.601% KYMR 501575104 US5015751044 BMPRZV5 466719.7.0 Fidelity Distributors Company, LLC 500 Salem Street Not Part of Annual or Semiannual Report Smithfield, RI 02917 3 % of Net Security Name Market Value Assets Ticker CUSIP ISIN SEDOL Morphic Holding, Inc. $46,403,518 0.592% MORF 61775R105 US61775R1059 BK8M4J4 Ionis Pharmaceuticals, Inc. $46,301,584 0.591% IONS 462222100 US4622221004 BDJ0LS6 Horizon Therapeutics PLC $45,962,091 0.587% HZNP IE00BQPVQZ61 BQPVQZ6 Prothena Corp. PLC $44,288,901 0.565% PRTA IE00B91XRN20 B91XRN2 Sarepta Therapeutics, Inc. $44,125,051 0.563% SRPT 803607100 US8036071004 B8DPDT7 Y-mAbs Therapeutics, Inc. $44,055,570 0.562% YMAB 984241109 US9842411095 BG31GH0 Relay Therapeutics, Inc. $42,818,951 0.547% RLAY 75943R102 US75943R1023 BN2R582 Protagonist Therapeutics, Inc. $39,404,509 0.503% PTGX 74366E102 US74366E1029 BDCBCD8 Crinetics Pharmaceuticals, Inc. $38,174,902 0.487% CRNX 22663K107 US22663K1079 BDD19F8 Agios Pharmaceuticals, Inc. $38,133,975 0.487% AGIO 00847X104 US00847X1046 BCBVTX1 Twist Bioscience Corp. $37,819,541 0.483% TWST 90184D100 US90184D1000 BGKG6G7 ALX Oncology Holdings, Inc. $37,671,062 0.481% ALXO 00166B105 US00166B1052 BLN7XQ1 BridgeBio Pharma, Inc. $37,241,875 0.475% BBIO 10806X102 US10806X1028 BK1KWG8 BioAtla, Inc. $37,173,011 0.474% BCAB 09077B104 US09077B1044 BNC5F86 Denali Therapeutics, Inc. $36,438,023 0.465% DNLI 24823R105 US24823R1059 BD2B4V0 Replimune Group, Inc. $34,501,249 0.440% REPL 76029N106 US76029N1063 BDDVW37 Zentalis Pharmaceuticals, Inc. $33,971,020 0.434% ZNTL 98943L107 US98943L1070 BMQ5T49 Arcturus Therapeutics Holdings, Inc. $33,594,910 0.429% ARCT 03969T109 US03969T1097 BKC9SX3 National Resilience, Inc. Series B $32,510,962 0.415% NRS+BPP Intra-Cellular Therapies, Inc. $31,823,086 0.406% ITCI 46116X101 US46116X1019 BHCB0P4 Monte Rosa Therapeutics, Inc. $31,636,155 0.404% GLUE.TMP CRISPR Therapeutics AG $31,528,372 0.402% CRSP CH0334081137 BDHF4K6 Translate Bio, Inc. $29,954,187 0.382% TBIO 89374L104 US89374L1044 BG88WT0 Allakos, Inc. $29,908,434 0.382% ALLK 01671P100 US01671P1003 BDD19P8 Celldex Therapeutics, Inc. $29,316,875 0.374% CLDX 15117B202 US15117B2025 BJLV8T9 Turning Point Therapeutics, Inc. $28,821,176 0.368% TPTX 90041T108 US90041T1088 BJXBP30 Macrogenics, Inc. $28,350,816 0.362% MGNX 556099109 US5560991094 BFDV8K0 Xencor, Inc. $27,882,248 0.356% XNCR 98401F105 US98401F1057 BGCYWN8 ChemoCentryx, Inc. $26,894,013 0.343% CCXI 16383L106 US16383L1061 B6ZL968 Cerevel Therapeutics Holdings $26,238,397 0.335% CERE 15678U128 US15678U1280 BMVMJ12 Karuna Therapeutics, Inc. $26,191,902 0.334% KRTX 48576A100 US48576A1007 BJMLSD2 C4 Therapeutics, Inc. $24,990,182 0.319% CCCC 12529R107 US12529R1077 BKX9NQ0 Graphite Bio, Inc. $23,154,404 0.296% GRH.TMP Ambrx Biopharma, Inc. ADR $22,913,810 0.292% AMA.TMP Zymeworks, Inc. $22,758,068 0.290% ZYME 98985W102 CA98985W1023 BYQHPK7 23andMe Holding Co. Class B $22,654,050 0.289% MEB.TMP 10X Genomics, Inc. $22,522,448 0.287% TXG 88025U109 US88025U1097 BKS3RS7 Revolution Medicines, Inc. $22,496,491 0.287% RVMD 76155X100 US76155X1000 BL71K91 Roivant Sciences Ltd. $22,297,500 0.285% MAAC.TMP 466719.7.0 Fidelity Distributors Company, LLC 500 Salem Street Not Part of Annual or Semiannual Report Smithfield, RI 02917 4 % of Net Security Name Market Value Assets Ticker CUSIP ISIN SEDOL Kura Oncology, Inc. $21,796,322 0.278% KURA 50127T109 US50127T1097 BYZD465 Iovance Biotherapeutics, Inc. $21,570,254 0.275% IOVA 462260100 US4622601007 BF0DMK7 Alector, Inc. $21,340,244 0.272% ALEC 014442107 US0144421072 BJ4LDC4 Sage Therapeutics, Inc. $20,808,265 0.266% SAGE 78667J108 US78667J1088 BP4GNK9 Instil Bio, Inc. $20,463,640 0.261% TIL.TMP Rallybio Corp. $20,345,345 0.260% RLYB 75120L100 US75120L1008 BMGTPL0 Arcutis Biotherapeutics, Inc.
Load more

Recommended publications
  • ARK GENOMIC REVOLUTION MULTI SECTOR ETF (ARKG) HOLDINGS As of 09/27/2021
    ARK GENOMIC REVOLUTION MULTI SECTOR ETF (ARKG) HOLDINGS As of 09/27/2021 Company Ticker CUSIP Shares Market Value($) Weight(%) 1 TELADOC HEALTH INC TDOC 87918A105 3,937,797 531,208,815.30 6.99 2 EXACT SCIENCES CORP EXAS 30063P105 3,971,013 381,296,668.26 5.01 3 PACIFIC BIOSCIENCES OF CALIF PACB 69404D108 13,696,148 350,347,465.84 4.61 4 VERTEX PHARMACEUTICALS INC VRTX 92532F100 1,722,281 316,228,014.41 4.16 5 FATE THERAPEUTICS INC FATE 31189P102 4,825,395 312,926,865.75 4.12 6 IONIS PHARMACEUTICALS INC IONS 462222100 8,572,965 310,341,333.00 4.08 7 REGENERON PHARMACEUTICALS REGN 75886F107 430,742 275,201,063.80 3.62 8 TWIST BIOSCIENCE CORP TWST 90184D100 2,237,350 250,829,308.50 3.30 9 TAKEDA PHARMACEUTIC-SP ADR TAK UN 874060205 13,592,076 229,570,163.64 3.02 10 ACCOLADE INC ACCD 00437E102 5,268,242 226,850,500.52 2.98 11 INTELLIA THERAPEUTICS INC NTLA 45826J105 1,508,421 224,965,907.94 2.96 12 VEEVA SYSTEMS INC-CLASS A VEEV 922475108 741,198 222,307,516.14 2.92 13 CAREDX INC CDNA 14167L103 3,433,475 220,978,451.00 2.91 14 CRISPR THERAPEUTICS AG CRSP H17182108 1,804,041 210,044,493.63 2.76 15 INCYTE CORP INCY 45337C102 2,893,385 199,643,565.00 2.63 16 INVITAE CORP NVTA 46185L103 6,059,066 182,135,523.96 2.40 17 ADAPTIVE BIOTECHNOLOGIES ADPT 00650F109 4,888,391 178,377,387.59 2.35 18 BEAM THERAPEUTICS INC BEAM 07373V105 1,849,698 175,110,909.66 2.30 19 SIGNIFY HEALTH INC -CLASS A SGFY 82671G100 8,107,683 160,937,507.55 2.12 20 UIPATH INC - CLASS A PATH 90364P105 2,955,628 155,761,595.60 2.05 21 CASTLE BIOSCIENCES INC CSTL 14843C105 2,130,211
    [Show full text]
  • United States Securities and Exchange Commission Washington, D.C
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2020 INTELLIA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37766 36-4785571 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Number) Identification No.) 40 Erie Street, Suite 130 Cambridge, Massachusetts 02139 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: (857) 285-6200 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Trading Name of each exchange Title of each class Symbol(s) on which registered Common Stock (Par Value $0.0001) NTLA The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
    [Show full text]
  • Questions About CRISPR
    CRISPR Questions about CRISPR A huge industry will grow from its innovation, but the IP environment around CRISPR is far from established. Marc Döring and Daniel Lim investigate The discovery of the potential of CRISPR and its first Cas system for various applications. characterisation in the form of the CRISPR/Cas9 system One group comprises Intellia, Caribou Biosciences (Caribou), represents a true revolution in the life sciences field. It is best Caribou founder Jennifer Doudna and the University of California, known as a method that allows for the accurate and targeted cutting Berkeley (UCB). That group is broadly aligned with CRISPR Tx, ERS of DNA to enable editing of genes, but variants can accomplish a Genomics and its founder Emmanuelle Charpentier, who collaborated wide range of other extremely useful effects, including modulation of with Doudna and co-owner of UCB’s foundational CRISPR patents. On gene expression. The power and versatility of the system has opened 16 December 2016, the Doudna and Charpentier camps formalised the door to advances in a wide range of industries, including human their alliance, signing a global cross-licensing and patent prosecution therapeutics, animal health, agriculture and bioindustry. CRISPR has the co-operation agreement. potential to revolutionise any industry in which molecular biology and Opposing them is Editas, its founder Feng Zhang and the Broad genetic technology play a part. Institute of MIT and Harvard (the Broad), who hold a separate, However, despite the clear potential of the technology, and leaving competing portfolio of foundational CRISPR/Cas9 patents. aside the significant amount of research and development still to be These spin-out companies have wasted no time in partnering undertaken, question marks linger over the legal and regulatory position variously with big pharma, venture capitalists and fellow disruptive of CRISPR technology and CRISPR-based products.
    [Show full text]
  • Market Deep Dive Report CRISPR Therapeutics June 2020
    Market Deep Dive Report CRISPR Therapeutics June 2020 Contents 1. Summary 3 2. Market Overview 3 2.1 Industry Challenges 4 2.2 Intellectual Property 5 2.3 Regulatory Requirements 5 2.4 Pitchbook Market Statistics 6 3. Technology Overview 6 3.1 Basic Summary 6 3.2 Base Editing 7 3.3 Prime Editing 8 3.4 Ex-Vivo CRISPR 9 3.5 In-Vivo CRISPR 10 3.6 Alternative techniques and platforms 11 3.7 Late stage privates & publics 13 3.8 Key People and Labs 13 4. Therapeutic Landscape 14 4.1 Present day status 14 4.2 Future Indications 16 4.3 Startups to Watch 17 5. Conclusions 18 5.1 Vertical Strengths 18 5.2 Vertical Weaknesses 18 5.3 Opportunity Cost of Capital 19 5.4 Investment Theses 19 6. References 20 2 1. Summary Since its initial discovery as a genetic reprogramming tool in 2012, CRISPR has widely been regarded as a breakthrough scientific discovery and quickly become one of the hottest new biotechnologies in the industry. However, the CRISPR therapeutics market is still in early stages, with leading therapies only just reaching human clinical trials. Furthermore, the industry is highly defended by IP, and currently addresses a narrow set of indications. Top companies including Beam Therapeutics, Editas Medicine, and Prime Medicine have been founded by the same scientists, and have formed a highly collaborative moat. Remaining companies have partnered with large pharmaceutical companies to fund operations. The future of CRISPR therapeutics development is dependent on technological advances in delivery methods and editing safety and granularity.
    [Show full text]
  • Intellia Therapeutics Annual Report 2021
    Intellia Therapeutics Annual Report 2021 Form 10-K (NASDAQ:NTLA) Published: February 26th, 2021 PDF generated by stocklight.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37766 INTELLIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 36-4785571 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 40 Erie Street, Suite 130 Cambridge, Massachusetts 02139 (Address of principal executive offices) (Zip Code) (857) 285-6200 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each Class Trade Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share NTLA The Nasdaq Global Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • News & Analysis
    NEWS & ANALYSIS NEWS IN BRIEF Intellia Therapeutics and partner Alzheimer prevention failure rattles field, anew Regeneron are working towards a 2020 investigational new drug application for Failed trials of amyloid- modulating Alzheimer disease candidates don’t come as much of a their in vivo NTLA-2001, a systemically surprise any more. But with Amgen and Novartis’s recent decision to halt two phase III trials delivered CRISPR treatment for transthyretin of the BACE1 inhibitor umibecestat for secondary prevention of the neurodegenerative amyloidosis. disease in high-risk patients, a longer shadow has now fallen on the prospects for these Asher Mullard agents in earlier lines of treatment as well. In the Generation S1 trial, the sponsors were testing umibecestat and the amyloid vaccine CAD106 in cognitively unimpaired individuals aged 60 to 75 years with two APOE4 genes, a risk factor for developing Alzheimer disease. In Generation S2, they were testing Longer- lasting HIV drugs umibecestat in cognitively unimpaired participants aged 60 to 75 years with at least one Antiretroviral therapies have revolutionized APOE4 allele. But in July the companies announced that the drug was associated with AIDS care, changing what was once a death worsening in some measures of cognitive function, and discontinued development of the sentence into a chronic and controllable BACE inhibitor. condition. But antiretroviral therapy (ART) After past failures of amyloid-modulating drugs, researchers have posited that these cocktails still have to be taken on a daily agents need to be used earlier in the course of disease — potentially years before symptoms basis, and treatment interruptions can result are detectable — to prevent neuronal death.
    [Show full text]
  • CRISPR Genome-Editing
    CRISPR Genome-Editing The Value of CRISPR’s IP Published: August 17, 2018 Author Manisha Samy, Analyst at ARK Invest Join the conversation on Twitter @ARKinvest www.ark-invest.com The Value of CRISPR’s Intellectual Property Manisha Samy THE VALUE OF INTELLECTUAL PROPERTY Intellectual property (IP) can be critical not only to commercial success but also to platform strategies upon which more innovation can take place. A strong patent portfolio might not guarantee success, but it can serve as a strategic asset, particularly in biotech. Patents provide a company with 20 years of exclusivity to advance innovations before others can compete. In the meantime, these companies receive licensing fees and/or royalty payments, but perhaps more importantly, attract talent seeking unfettered access to cutting edge technology. Genentech is a prime example of the benefits of a strong IP position in the field of health care. In 1980, Genentech went public, largely on the strength of its IP in recombinant DNA technology.1 Attracting some of biotech’s brightest minds, it commercialized synthetic insulin two years later, four years before Roche took a majority interest. Genentech’s stock scaled 11-fold at a 47% compound annual rate in the six years between its initial public offering (IPO) and Roche taking majority interest. CRISPR’S IP LANDSCAPE While Genentech benefited from a patent claim that was unambiguous, the CRISPR IP landscape is much more convoluted. In a high-profile patent battle between the University of California (UC), Berkeley and the Broad Institute, scientists are fighting for commercial claims to the “foundational” CRISPR IP.
    [Show full text]
  • CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S
    CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology The interference proceeding remains terminated without any determination on inventorship of CRISPR/Cas9 genome editing application to eukaryotic cells University of California/University of Vienna/Dr. Charpentier have patent applications covering the use of CRISPR/Cas9 genome editing technology in all environments that do not interfere with the Broad’s patent claims in this proceeding Additional legal paths are available to recognize the priority of the University of California/University of Vienna/Charpentier intellectual property covering eukaryotic cells University of California/University of Vienna/Dr. Charpentier were recently issued a U.S. patent for the use of CRISPR/Cas9 genome editing that covers guide formats widely used across the human therapeutic and agricultural industries ZUG, Switzerland and CAMBRIDGE, Mass. and BERKELEY, Calif., Sept. 10, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (NASDAQ:CRSP), Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Caribou Biosciences, Inc. announced that the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”) affirmed the decision by the U.S. Patent and Trademark Office’s (“USPTO”) Patent Trial and Appeal Board (“PTAB”) in an interference proceeding relating to CRISPR/Cas9 genome editing technology. The interference was requested by the Regents of the University of California, the University of Vienna and Dr. Emmanuelle Charpentier (collectively “UC”), co-owners of foundational intellectual property relating to CRISPR/Cas9 genome engineering, against the Broad Institute, Harvard University and the Massachusetts Institute of Technology (collectively “Broad”).
    [Show full text]
  • INTELLIA THERAPEUTICS, INC. (Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.14a-12 INTELLIA THERAPEUTICS, INC. (Name of registrant as specified in its charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒ No fee required. ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ☐ Fee paid previously with preliminary materials. ☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: INTELLIA THERAPEUTICS, INC.
    [Show full text]
  • Nobel Laureate Jennifer Doudna and the Bio Revolution Catalyst COLLEGE of CHEMISTRY UNIVERSITY of CALIFORNIA, BERKELEY
    SP21 V 16.1 Spring/Summer 2021 Volume 16 • Issue 1 COLLEGE OFCatalyst CHEMISTRY • UNIVERSITY OF CALIFORNIA, BERKELEY Nobel Laureate Jennifer Doudna and the bio revolution Catalyst COLLEGE OF CHEMISTRY UNIVERSITY OF CALIFORNIA, BERKELEY dean Douglas S. Clark [email protected] executive associate dean Richmond Sarpong [email protected] chair, department of chemistry Matthew B. Francis [email protected] chair, department of chemical and biomolecular engineering Jeffrey A. Reimer [email protected] undergraduate dean John Arnold [email protected] senior assistant dean, college relations & development 7 Laurent “Lo” de Janvry [email protected] senior director of development Mindy Rex [email protected] senior director, strategic and philanthropic partnerships Camille M. Olufson [email protected] managing editor director marketing and communications Marge d’Wylde catalyst online Leigh Moyer contributors 12 Ashok Ajoy Laurent de Janvry Denise Klarquist Mark Kubinec Brice Yates research Sara Koerber design Alissar Rayes printing Dome Printing for submissions to college publications, please email content to: [email protected] 6 ON THE COVER In this issue, we celebrate Professor Jennifer Doudna’s Nobel Prize and the bio revolution she has helped create. COVER PHOTO: KEEGAN HOUSER catalyst online at: catalyst.berkeley.edu © 2021, Regents of the University of California contents Spring/Summer 2021 Volume 16 • Issue 1 3 DEAN’S DESK 16 The new era in theoretical chemistry 4 NEW & NOTABLE 18 MARTIN HEAD-GORDON 20 BIRGITTA WHALEY 8 FUTURE TECH 22 PHILLIP GEISSLER 24 ERAN RABANI 12 Nobel Laureate Jennifer Doudna and the bio revolution 26 NEW FACULTY PROFILES 32 DONOR SPOTLIGHT 36 EDITORIAL 16 32 26 28 30 36 College of Chemistry, UC Berkeley PHOTO © BENSONPHOTOS, ALL RIGHTS RESERVED.
    [Show full text]
  • CRISPR Steps Closer to Centre Stage As Astrazeneca Piles In
    January 29, 2015 CRISPR steps closer to centre stage as AstraZeneca piles in Amy Brown Maxed out on CAR-T and looking for the next field of novel and cutting-edge science to capture the imagination of investors? Look no further than CRISPR, the hot gene-editing technology with a rapidly rising profile, into which AstraZeneca swooped today in a pretty big way. True, CRISPR is at an even earlier stage than CAR-T and its therapeutic applications are considerably further from the market. But the fields are connected – some CAR-T companies are using gene-editing techniques – and also display similarities; the largely academic-led space has been born of much scientific cross-fertilisation, and IP squabbles loom large. As long as the stock markets remain so receptive to risk, it will surely not be long before public investors can get involved. Currently there are only three companies, all private, that have declared a dedication to the use of CRISPR to develop drugs: Editas Medicine, Intellia Therapeutics and Crispr Therapeutics. CRISPR, a third-generation gene-editing technology, follows in the wake of zinc finger and TALEN platforms. The idea is the same, although rather than using large, unwieldy proteins to guide a DNA-cutting enzyme to its target, like the earlier incarnations, CRISPR uses tiny strands of RNA. The result is a much more precise tool that allows multiple genetic deletions or edits to be made, with huge implications for the cost and time of experiments. So it is not surprising that CRISPR has attracted a fair amount of commercial interest in a very short space of time.
    [Show full text]
  • INTELLIA THERAPEUTICS, INC. (Exact Name of Registrant As Specified in Its Charter) Delaware 36-4785571 (State Or Other Jurisdiction of (I.R.S
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37766 INTELLIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 36-4785571 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 40 Erie Street, Suite 130 Cambridge, Massachusetts 02139 (Address of principal executive offices) (Zip Code) (857) 285-6200 (Registrants telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each Class Trade Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share NTLA The Nasdaq Global Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]